LOGIXX_PHARMA_SOLUTIONS_L - Accounts

Company Registration No. 07209211 (England and Wales)
LOGIXX PHARMA SOLUTIONS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019
PAGES FOR FILING WITH REGISTRAR
LOGIXX PHARMA SOLUTIONS LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 8
LOGIXX PHARMA SOLUTIONS LIMITED
BALANCE SHEET
AS AT
31 MARCH 2019
31 March 2019
- 1 -
2019
2018
Notes
£
£
£
£
Fixed assets
Tangible assets
3
21,868
547
Investments
4
101,000
-
122,868
547
Current assets
Stocks
1,623,703
666,620
Debtors
5
2,011,670
1,845,403
Cash at bank and in hand
304,526
291,078
3,939,899
2,803,101
Creditors: amounts falling due within one year
6
(2,720,537)
(1,691,941)
Net current assets
1,219,362
1,111,160
Total assets less current liabilities
1,342,230
1,111,707
Creditors: amounts falling due after more than one year
7
-
(26,212)
Provisions for liabilities
(3,707)
-
Net assets
1,338,523
1,085,495
Capital and reserves
Called up share capital
8
1,000
1,000
Profit and loss reserves
1,337,523
1,084,495
Total equity
1,338,523
1,085,495

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

LOGIXX PHARMA SOLUTIONS LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 MARCH 2019
31 March 2019
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 23 December 2019 and are signed on its behalf by:
Mr M S Close
Director
Company Registration No. 07209211
LOGIXX PHARMA SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019
- 3 -
1
Accounting policies
Company information

LogixX Pharma Solutions Limited is a private company limited by shares incorporated in England and Wales. The registered office is Central House Rear Office, 124 High Street, Hampton Hill, Middlesex, England, TW12 1NS.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Equipment
25% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

LOGIXX PHARMA SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2019
1
Accounting policies
(Continued)
- 4 -
1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans and loans from fellow group companies are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

LOGIXX PHARMA SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2019
1
Accounting policies
(Continued)
- 5 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.12
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.13
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in the profit and loss account for the period.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was 12 (2018 - 9).

LOGIXX PHARMA SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2019
- 6 -
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 April 2018
5,461
Additions
28,242
At 31 March 2019
33,703
Depreciation and impairment
At 1 April 2018
4,914
Depreciation charged in the year
6,921
At 31 March 2019
11,835
Carrying amount
At 31 March 2019
21,868
At 31 March 2018
547
4
Fixed asset investments
2019
2018
£
£
Investments
101,000
-
Movements in fixed asset investments
Investments other than loans
£
Cost or valuation
At 1 April 2018
-
Additions
101,000
At 31 March 2019
101,000
Carrying amount
At 31 March 2019
101,000
At 31 March 2018
-
LOGIXX PHARMA SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2019
- 7 -
5
Debtors
2019
2018
Amounts falling due within one year:
£
£
Trade debtors
470,437
1,166,646
Amounts owed by group undertakings
577,875
-
Other debtors
963,358
678,757
2,011,670
1,845,403
6
Creditors: amounts falling due within one year
2019
2018
£
£
Bank loans
27,303
27,675
Trade creditors
2,156,890
927,353
Corporation tax
117,952
360,813
Other taxation and social security
263,852
349,344
Other creditors
154,540
26,756
2,720,537
1,691,941

Bank loans of £27,303 (2018 - £27,675) are secured by fixed and floating charges over the company's assets.

7
Creditors: amounts falling due after more than one year
2019
2018
£
£
Bank loans and overdrafts
-
26,212

In the prior year Bank loans of £26,212 were secured by fixed and floating charges over the company's assets.

8
Called up share capital
2019
2018
£
£
Ordinary share capital
Issued and fully paid
1,000 Ordinary shares of £1 each
1,000
1,000
LOGIXX PHARMA SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2019
- 8 -
9
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2019
2018
£
£
65,030
-
10
Related party transactions
Transactions with related parties

During the year the company entered into the following transactions with related parties:

Purchases
2019
2018
£
£
Other related parties
1,082,112
1,422,085
Services provided
2019
2018
£
£
Other related parties
178,683
171,560

The following amounts were outstanding at the reporting end date:

2019
2018
Amounts due from related parties
£
£
Entities with control, joint control or significant influence over the company
577,875
-
Other related parties
722,805
654,681
2019-03-312018-04-01false23 December 2019CCH SoftwareCCH Accounts Production 2019.301supply of pharmaceutical products

Mr M S CloseMr K J WilliamsMr M S Close
072092112018-04-012019-03-31072092112019-03-31072092112018-03-3107209211core:OtherPropertyPlantEquipment2019-03-3107209211core:OtherPropertyPlantEquipment2018-03-3107209211core:CurrentFinancialInstrumentscore:WithinOneYear2019-03-3107209211core:CurrentFinancialInstrumentscore:WithinOneYear2018-03-3107209211core:CurrentFinancialInstruments2019-03-3107209211core:CurrentFinancialInstruments2018-03-3107209211core:Non-currentFinancialInstruments2018-03-3107209211core:ShareCapital2019-03-3107209211core:ShareCapital2018-03-3107209211core:RetainedEarningsAccumulatedLosses2019-03-3107209211core:RetainedEarningsAccumulatedLosses2018-03-3107209211bus:CompanySecretaryDirector12018-04-012019-03-3107209211core:ComputerEquipment2018-04-012019-03-31072092112017-04-012018-03-3107209211core:OtherPropertyPlantEquipment2018-03-3107209211core:OtherPropertyPlantEquipment2018-04-012019-03-3107209211core:WithinOneYear2019-03-3107209211core:WithinOneYear2018-03-3107209211core:CurrentFinancialInstrumentscore:Secured2019-03-3107209211core:Secured2018-03-3107209211core:Non-currentFinancialInstrumentscore:Secured2018-03-3107209211core:OtherRelatedParties2018-04-012019-03-3107209211core:OtherRelatedParties2017-04-012018-03-3107209211core:OtherMembersGroupNotDefinedElsewherecore:OtherTransactionType12019-03-3107209211core:OtherRelatedParties2019-03-3107209211core:OtherRelatedParties2018-03-3107209211bus:PrivateLimitedCompanyLtd2018-04-012019-03-3107209211bus:SmallCompaniesRegimeForAccounts2018-04-012019-03-3107209211bus:FRS1022018-04-012019-03-3107209211bus:AuditExemptWithAccountantsReport2018-04-012019-03-3107209211bus:Director12018-04-012019-03-3107209211bus:Director22018-04-012019-03-3107209211bus:CompanySecretary12018-04-012019-03-3107209211bus:FullAccounts2018-04-012019-03-31xbrli:purexbrli:sharesiso4217:GBP